Premium
[IC‐02–02]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]‐AV‐1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE
Author(s) -
Mishra Shruti,
Gordon Brian A.,
Blazey Tyler,
Su Yi,
Christensen Jon,
Jackson Kelley,
Hornbeck Russ C.,
Morris John C.,
Ances Beau M.,
Benzinger Tammie L.S.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.2627
Subject(s) - entorhinal cortex , atrophy , nuclear medicine , positron emission tomography , standardized uptake value , magnetic resonance imaging , neuroimaging , alzheimer's disease , medicine , primary progressive aphasia , temporal cortex , psychology , neurodegeneration , dementia , pathology , neuroscience , hippocampus , radiology , disease , frontotemporal dementia
injection of 18F-PI-2620. Venous blood is obtained to characterize the kinetics of parent compound andmetabolites. Results:Initial imaging data shows robust brain uptake and fast wash-out in nontarget regions with peak SUV 1⁄4 4-4.5. There was no increased uptake seen in choroid plexus, striatum, amygdala, or other regions noted in first generation tau agents. In AD, focal asymmetric uptake was evident in temporal and parietal lobes, precuneus, and cingulate. SUVr time curves demonstrate a plateau at 90-100 min post injection with resultant SUVrs of 2.5-2.8.in abnormal regions, whilst HV demonstrated shorter time to secular equilibrium (6070 min) and lower SUVrs (1.0-1.2) in comparable brain regions. Finally, PSP subjects demonstrated focal and symmetric increased uptake in the globus (SUVr1⁄41.99-2.11) and midbrain (SUVr1⁄42.41-2.58). Blood data confirmed fast kinetics with 20% of parent compound present at 60 min and the presence of polar metabolites. Conclusions: Initial PI-2620 PET first-in-human studies demonstrate excellent brain penetrance, favorable kinetics, and high target specificity with low nonspecific binding and high signal in regions of expected tau pathology.